Pages that link to "Q43040909"

The following pages link to Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. (Q43040909):

Displaying 41 items.

• Challenges of recurrent hepatitis C in the liver transplant patient (Q27011871) (← links)
• Managing chronic hepatitis C in the difficult-to-treat patient (Q27490409) (← links)
• Diagnosis, management, and treatment of hepatitis C: an update (Q29619682) (← links)
• Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future (Q34093754) (← links)
• Treatment of chronic hepatitis C in patients with Crohn's disease (Q34178776) (← links)
• Antiviral treatment for hepatitis C virus infection after liver transplantation (Q34340293) (← links)
• Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat (Q34628400) (← links)
• Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010. (Q34684679) (← links)
• Treatment of hepatitis C virus infection in the allograft (Q35572085) (← links)
• Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. (Q35688896) (← links)
• Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. (Q36028318) (← links)
• Amantadine in treatment of chronic hepatitis C virus infection? (Q36234125) (← links)
• Liver transplantation for hepatitis C virus related liver disease (Q36339458) (← links)
• Management of hepatitis C in liver transplant recipients. (Q36392142) (← links)
• Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis (Q36530402) (← links)
• Rejection under alpha interferon therapy in liver transplant recipients (Q36709673) (← links)
• Hepatitis C virus infection--pathobiology and implications for new therapeutic options (Q36749431) (← links)
• Management of hepatitis C infection after liver transplantation (Q36788362) (← links)
• New perspectives for preventing hepatitis C virus liver graft infection (Q37015805) (← links)
• Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation (Q37630394) (← links)
• Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation (Q37810315) (← links)
• Management of hepatitis C virus infection recurrence after liver transplantation: an overview. (Q37844982) (← links)
• Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. (Q38081919) (← links)
• Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection (Q39007700) (← links)
• Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. (Q41137675) (← links)
• Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. (Q41172899) (← links)
• Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. (Q42996792) (← links)
• Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation (Q42998971) (← links)
• Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. (Q43001526) (← links)
• Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection (Q43030458) (← links)
• Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation (Q43030470) (← links)
• Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. (Q43032973) (← links)
• Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation (Q43061683) (← links)
• The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. (Q43224173) (← links)
• Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. (Q45415931) (← links)
• Treatment of hepatitis C virus in the liver transplant recipient (Q45710863) (← links)
• Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years (Q46646250) (← links)
• Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management (Q50574546) (← links)
• Antiviral therapy for hepatitis C in the setting of liver transplantation (Q50574871) (← links)
• Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment (Q50576993) (← links)
• Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome (Q62804139) (← links)